Deborah Kay Armstrong

Professor

1979 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 9 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Platinum Medicine & Life Sciences
Carboplatin Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1979 2018

New therapies for ovarian cancer

Armstrong, D. K., May 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 5S, p. 632-635 4 p.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Guidelines
Adenosine Diphosphate Ribose
Poly Adenosine Diphosphate Ribose
Therapeutics

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Provencher, D. M. , Gallagher, C. J. , Parulekar, W. R. , Ledermann, J. A. , Armstrong, D. K. , Brundage, M. , Gourley, C. , Romero, I. , Gonzalez-Martin, A. , Feeney, M. , Bessette, P. , Hall, M. , Weberpals, J. I. , Hall, G. , Lau, S. K. , Gauthier, P. , Fung-Kee-Fung, M. , Eisenhauer, E. A. , Winch, C. , Tu, D. & 1 others MacKay, H. J., Feb 1 2018, In : Annals of Oncology. 29, 2, p. 431-438 8 p.

Research output: Contribution to journalArticle

Carboplatin
Ovarian Neoplasms
Drug Therapy
Paclitaxel
Neoplasms

OV21/PETROC: A randomized gynecologic cancer intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Provencher, D. M. , Gallagher, C. J. , Parulekar, W. R. , Ledermann, J. A. , Armstrong, D. K. , Brundage, M. , Gourley, C. , Romero, I. , Gonzalez-Martin, A. , Feeney, M. , Bessette, P. , Hall, M. , Weberpals, J. I. , Hall, G. , Lau, S. K. , Gauthier, P. , Fung-Kee-Fung, M. , Eisenhauer, E. A. , Winch, C. , Tu, D. & 1 others Mackay, H. J., Apr 1 2018, In : Obstetrical and Gynecological Survey. 73, 4, p. 209-210 2 p.

Research output: Contribution to journalComment/debate

Drug Therapy
Neoplasms
Ovarian epithelial cancer

Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors

Hyman, D. M., Rizvi, N., Natale, R., Armstrong, D. K., Birrer, M., Recht, L., Dotan, E., Makker, V., Kaley, T., Kuruvilla, D., Gribbin, M., McDevitt, J., Lai, D. W. & Dar, M., Jun 15 2018, In : Clinical Cancer Research. 24, 12, p. 2749-2757 9 p.

Research output: Contribution to journalArticle

Angiopoietin-2
Carboplatin
Paclitaxel
Ovarian Neoplasms
Neoplasms

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer

Litvak, A., Batukbhai, B., Russell, S. D., Tsai, H. L., Rosner, G. L., Jeter, S. C., Armstrong, D., Emens, L. A., Fetting, J., Wolff, A. C., Silhy, R., Stearns, V. & Connolly, R. M., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Confidence Intervals
Stroke Volume
Incidence